Drug Pricing: Page 2


  • A view from below of the CVS sign on the center of a building, with a vertical blue HealthHub sign to its right.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    CVS launches new venture in biosimilar drug experiment

    The subsidiary, called Cordavis, will work directly with manufacturers to market or co-produce low-cost biologic drugs, starting with Novartis’ Humira copy.

    By Aug. 24, 2023
  • Boehringer sues to block US drug price program

    The pharma’s suit, which claims Medicare’s new power to negotiate certain drug prices is unconstitutional, comes days before the agency will reveal the first 10 medicines to be included under the plan.

    By Aug. 22, 2023
  • Explore the Trendline
    Image attribution tooltip
    Elizabeth Regan / Biopharma Blog
    Image attribution tooltip
    Trendline

    Drug pricing

    Drug pricing legislation has put pharmaceutical companies on the defensive and created a new precedent for the industry.

    By BioPharma Blog staff
  • A picture of the exterior of a CVS Pharmacy with the logo and name in view.
    Image attribution tooltip
    Bruce Bennett via Getty Images
    Image attribution tooltip

    Blue Shield of California drops CVS Caremark in pharmacy benefit overhaul

    BSCA has kicked CVS Caremark, the largest pharmacy benefit manager in the country, to the curb and is electing to carve out various pharmacy functions with companies like Amazon instead.

    By Rebecca Pifer • Updated Aug. 17, 2023
  • Alexis Borisy and Melanie Nallicheri of EQRx, at launch
    Image attribution tooltip
    Courtesy of EQRx
    Image attribution tooltip

    EQRx to sell to Revolution Medicines after failed bid to upend US drug pricing

    The all-stock deal is a quiet end for the ambitious biotech, which was sold for its billion-dollar bank account after the FDA derailed its plans to develop low-cost cancer medicines.

    By Aug. 1, 2023
  • A office building is seen with a sign reading "GlaxoSmithKline."
    Image attribution tooltip
    Leon Neal via Getty Images
    Image attribution tooltip
    RSV vaccines

    GSK confident in RSV vaccine launch, but sets expectations for ‘steady build’

    GSK expects its respiratory syncytial virus vaccine will be a multibillion dollar product. But at the beginning, it’s predicting a slower launch than for its fast-selling shingles shot.

    By July 27, 2023
  • An AbbVie sign is seen on a building at the pharmaceutical company's U.S. headquarters.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip
    Patent thickets

    Biosimilar makers split strategies in bid to take on top-selling Humira

    In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.

    By July 26, 2023
  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J joins pharma allies in challenging US drug pricing law

    The pharma claimed in federal court that the Inflation Reduction Act, which threatens sales of its blood thinner Xarelto, amounts to “confiscation of constitutionally protected property.”

    By Kristin Jensen • July 19, 2023
  • The U.S. Supreme Court is seen in spring through the branches of a tree.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Pharma’s strike-from-all-sides attack on the IRA could end up at the Supreme Court

    Industry lawsuits have taken a ‘multi-pronged’ approach to challenge the Inflation Reduction Act’s price negotiation program on constitutional grounds.

    By Alexandra Pecci • July 6, 2023
  • A photograph of the exterior of the Food and Drug Administration headquarters in Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Alvotech to raise cash after third FDA rejection for Humira biosimilar

    The latest regulatory setback, tied to continuing manufacturing issues, ensures Alvotech and partner Teva won’t be able to launch their drug alongside a wave of emerging Humira copycats.

    By Kristin Jensen • June 29, 2023
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Sarepta prices Duchenne gene therapy at $3.2M

    The cost makes Sarepta’s treatment among the most expensive medicines in the world. But company executives said they don’t expect significant insurer pushback.

    By June 22, 2023
  • An injector and box of Coherus BioScience's Yusimry drug.
    Image attribution tooltip
    Courtesy of Coherus BioSciences
    Image attribution tooltip

    AbbVie, Coherus mend dispute over low-price Humira biosimilar

    The biosimilar developer’s plans to set steep discounts on its copycat version of AbbVie’s Humira set off a legal back-and-forth between the companies.

    By Kristin Jensen • June 15, 2023
  • Prescriptions drugs on a production line.
    Image attribution tooltip
    zorazhuang via Getty Images
    Image attribution tooltip

    Pharmaceutical companies search for IRA response as they brace for drug pricing talks

    Lobbying group PhRMA does not expect any near-term changes to the IRA’s drug pricing provisions, but is attempting to lay groundwork for future changes.

    By June 15, 2023
  • A picture of the exterior of the US Department of Health and Human Services. In front of the building is a black sign designating the building's name.
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    Medicare sets next tranche of drugs to face price hike penalties

    CMS named 43 Part B drugs for which prices rose more than inflation, and which will have lower coinsurance rates next quarter as a result.

    By June 9, 2023
  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Merck sues to block Medicare negotiation of drug prices

    The drugmaker’s lawsuit claims the new pricing powers granted by the Inflation Reduction Act are unconstitutional and “tantamount to extortion.”

    By Updated June 6, 2023
  • An injector and box of Coherus BioScience's Yusimry drug.
    Image attribution tooltip
    Courtesy of Coherus BioSciences
    Image attribution tooltip

    Coherus sets steep discount for Humira copycat, plans direct sales

    The biotech will price its biosimilar Yusimry at 85% below Humira’s list price when it launches next month, and charge even less if bought through Mark Cuban’s pharmacy.

    By June 1, 2023
  • Rep. Comer sits in front of a poster outlining the cost differences between a drug dispensed at Cost Plus Drugs versus CVS.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Blog
    Image attribution tooltip

    House lawmakers, PBM lobby spar over committee hearing

    At the latest congressional inquiry into pharmacy benefit managers, lawmakers argued the middlemen profit at the expense of patients and taxpayers.

    By Rebecca Pifer • May 25, 2023
  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip
    AbbVie
    Image attribution tooltip

    AbbVie weathers first months of biosimilar challenge to top-selling Humira

    While Humira sales declined, the drop was mostly due to price concessions AbbVie made to secure equal insurer access in the face of copycat competition.

    By April 28, 2023
  • A picture of the exterior of the US Department of Health and Human Services. In front of the building is a black sign designating the building's name.
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    CMS removes 7 drugs from list marked for price hike penalties

    After revising its calculations, CMS removed Gilead’s cancer cell therapies Yescarta and Tecartus, as well as 5 other medicines, from the first set of drugs subject to rebates under a provision of the IRA.

    By March 31, 2023
  • An image of an Express Scripts prescription bottle.
    Image attribution tooltip
    Courtesy of Express Scripts
    Image attribution tooltip

    Ohio AG sues Cigna, Humana for alleged PBM price fixing

    The state’s Attorney General David Yost called pharmacy benefit managers “modern gangsters,” claiming in a suit filed Monday they shared pricing information and drove up drug prices.

    By Hailey Mensik • March 28, 2023
  • Senate Health, Education, Labor, and Pensions Committee Chairman Bernie Sanders waving a report as he questions Moderna CEO Stéphane Bancel at a March, 22, 2023 hearing.
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip

    Moderna CEO defends price of COVID shot at Senate hearing

    Stéphane Bancel said his company's planned quadrupling of the vaccine’s price covers the higher costs of commercial sales. Sen. Bernie Sanders called it part of industry’s “unprecedented level of corporate greed.”

    By March 22, 2023
  • A picture of Xavier Becerra giving a speech at a podium
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    U.S. government again rejects call to seize Xtandi rights

    The Biden administration plans to review federal “march-in” rights and consider whether price could be a reason to take control of patents for drugs developed with government funding.

    By March 22, 2023
  • A person holds an insulin pen
    Image attribution tooltip
    agrobacter via Getty Images
    Image attribution tooltip

    Sanofi joins other diabetes drugmakers in cutting insulin prices

    The pharma is the last of the three major insulin suppliers to reduce U.S. list prices, responding to persistent criticism and policy changes that will affect Medicaid rebate payments.

    By March 17, 2023
  • A picture of the exterior of the US Department of Health and Human Services. In front of the building is a black sign designating the building's name.
    Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    CMS lays out plans for negotiating drug prices

    The guidance fills in details for one of the central pharmaceutical provisions of the Inflation Reduction Act, signaling how the agency will use its new authority.

    By March 16, 2023
  • HHS Secretary Xavier Becerra speaks to reporters.
    Image attribution tooltip
    Justin Sullivan/Staff via Getty Images
    Image attribution tooltip

    US names first drugs to face price hike penalty

    Gilead’s cancer cell therapies Yescarta and Tecartus were among the slate of 27 drugs singled out by CMS for rebates under a provision of the IRA.

    By March 15, 2023
  • A flag with the Novo Nordisk logo.
    Image attribution tooltip
    Novo Nordisk
    Image attribution tooltip

    Novo Nordisk follows Lilly in sharply cutting insulin prices

    Responding to policy changes and pressure over high drug costs, the pharma is reducing the sticker price of four branded diabetes medicines by up to 75%.

    By March 14, 2023